HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.

Abstract
Six human ovarian cancer cell lines and samples of ascites cells isolated from 27 patients with stage III or IV ovarian papillary serous cystadenocarcinoma were studied individually to test whether recombinant human Mullerian inhibiting substance (rhMIS) acts via its receptor. To do these experiments, we scaled up production of rhMIS and labeled it successfully with biotin for binding studies, cloned the human MIS type II receptor for mRNA detection, and raised antibodies to an extracellular domain peptide for protein detection. These probes were first tested on the human ovarian cancer cell lines and then applied to primary ovarian ascites cells. rhMIS inhibited colony growth of five of six cell lines that expressed the human MIS type II receptor mRNA by Northern analysis while not inhibiting receptor-negative COS cells. Flow cytometry performed on MIS-sensitive ovarian cancer cell lines demonstrated specific and saturable binding of rhMIS (Kd = 10.2 nM). Ascites cells from 15 of 27 or 56% of patients tested bound biotinylated MIS (MIS-biotin) and, of the 11 that grew in soft agarose, 9 of 11 or 82% showed statistically significant inhibition of colony formation. Of the 15 patients who bound biotinylated MIS, mRNA was available for analysis from 9, and 8 of 9 expressed MIS type II receptor mRNA by reverse transcription-PCR, showing a statistically significant correlation, compared with binding, by chi2 analysis (P = 0.025). Solid ovarian cancers were positive for the MIS type II receptor protein by immunohistochemical staining, which colocalized with staining for antibody to CA-125 (OC-125). Thus, the detection of the MIS type I receptor by flow cytometry may be a useful predictor of therapeutic response to MIS and may be a modality to rapidly choose patients with late-stage ovarian cancer for treatment with MIS.
AuthorsP T Masiakos, D T MacLaughlin, S Maheswaran, J Teixeira, A F Fuller Jr, P C Shah, D J Kehas, M K Kenneally, D M Dombkowski, T U Ha, F I Preffer, P K Donahoe
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 5 Issue 11 Pg. 3488-99 (Nov 1999) ISSN: 1078-0432 [Print] United States
PMID10589763 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Glycoproteins
  • Growth Inhibitors
  • Peptide Fragments
  • Receptors, Peptide
  • Receptors, Transforming Growth Factor beta
  • Recombinant Proteins
  • Testicular Hormones
  • anti-Mullerian hormone receptor
  • Anti-Mullerian Hormone
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Amino Acid Sequence
  • Animals
  • Anti-Mullerian Hormone
  • Ascites (genetics, pathology)
  • COS Cells
  • Cell Division (drug effects)
  • Cystadenocarcinoma (genetics, pathology)
  • Female
  • Fetus
  • Glycoproteins
  • Growth Inhibitors (metabolism, pharmacology)
  • Humans
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Mullerian Ducts
  • Ovarian Neoplasms (genetics, pathology)
  • Peptide Fragments (chemistry, immunology)
  • Rats
  • Receptors, Peptide (genetics, metabolism)
  • Receptors, Transforming Growth Factor beta
  • Recombinant Proteins (metabolism)
  • Testicular Hormones (metabolism, pharmacology)
  • Testis (embryology, metabolism)
  • Transfection
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: